Services
Company
Legal and Governance
Publication Library / Publications
Real-world cost-effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropenia
Background
Real-world data suggests superiority of pegfilgrastim (PEG) over filgrastim (FIL) in reducing the incidence of chemotherapy-induced febrile neutropenia (FN), probably attributable to underdosed FIL in practice. We used real-world data to assess the cost-effectiveness of primary prophylaxis with PEG versus FIL in cancer patients at intermediate-to-high risk of FN from a US payer perspective.
Methods
A Markov model with lifetime horizon.
Results
For the high-risk group, PEG (vs FIL) biosimilars resulted in 0.43 FN events prevented (FNp), 0.27 quality-adjusted life-years gained (QALYg) and a cost saving of USD$5703. For the intermediate-risk group, PEG biosimilar led to 0.18 FNp and 0.12 QALYg, at USD$9674/FNp and USD$14,502/QALYg.
Conclusion
PEG biosimilars may provide opportunities to optimize FN management in patients with intermediate-to-high FN risk.
Authors
P Cornes, J Kelton, R Liu, O Zaidi, J Stephens, J Yang
Journal
Future oncology (London, England)
Therapeutic Area
Hematology
Center of Excellence
Health Economic Modeling & Meta-analysis
Year
2022
Read full article